Drogas legales emergentes: marihuana sintética, kratom, salvia divinorum, metoxetamina y los derivados de la piperazina

Bibliographic References

• Adkins, J.E., Boyer, E.W., McCurdy, C.R. (2011). Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Current Topics in Medicinal Chemistry, 11, (9), 1165–1175.
• Arndt, T., Claussen, U., Gussregen, B., Schrofel, S., Sturzer, B., Werle, A. et al (2011). Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. Forensic Science International, 208, (1–3), 47–52.
• Assanangkornchai, S., Muekthong, A., Sam-Angsri, N., Pattanasattayawong, U. (2007). The use of mitragynine speciosa (“Krathom”), an addictive plant, in Thailand. Substance Use & Misuse, 42, (14), 2145–2157.
• Auwarter, V., Dresen. S, Weinmann, W., Muller, M., Putz, M., Ferreiros, N. (2009). ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry, 44, (5), 832–837
• Aviello, G., Borrelli F, Guida, F., Romano, B., Lewellyn, K., De Chiaro, M. et ál. (2011). Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS stimulated murine macrophages and its anti-inflammatory action in vivo. Journal of Molecular Medicine (Berl.), 89, (9), 891–902.
• Baggott, M., Erowid, E., Erowid, F. (2004). A survey of Salvia divinorum users. Erowid Extracts, 6, 12–14.
• Baggott, M.J., Erowid. E., Erowid. F., Galloway, G.P., Mendelson. J. (2010). Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug and Alcohol Dependence, 111(3), 250–256.
• Boyer, E.W., Babu. K.M., Macalino. G.E. (2007). Self-treatment of opioid withdrawal with a dietary supplement, Kratom. The American Journal on Addictions, 16, (5), 352–356.
• Brown, S.M., Wager-Miller. J., Mackie. K. (2002). Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica et Biophysica Acta. 1576, (3), 255–264.
• Bye, C., Munro-Faure, A,D,, Peck, A.W., Young, P.A. (1973). A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. European Journal of Clinical Pharmacology, 6, (3), 163–169.
• Campbell, H., Cline. W., Evans. M., Lloyd, J., Peck, A.W. (1973). Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. European Journal of Clinical Pharmacology, 6,(3), 170–176.
• Chin, C.N., Murphy. J.W., Huffman. J.W., Kendall. D.A. (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics, 291, (2), 837–844.
• Cunningham, C.W., Rothman, R.B., Prisinzano, T.E. (2011). Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacological Reviews, 63, (2), 316–347.
• Davies, S., Wood, D.M., Smith, G., Button. J., Ramsey, J., Archer, R. et ál. (2010). Purchasing ‘legal highs’ on the Internet—is there consistency in what you get? QJM: Monthly Journal of the Association of Physicians, 103, (7), 489–493.
• Drug Enforcement Agency (2010). Drugs and chemicals of concern: N benzylpiperazine.
• Erowid Experience Vaults—Methoxetamine (2011). First time for and experienced K lover. http://www.erowid.org/experiences/exp. php?ID088687. Accessed 17 July 2011.
• Erowid Experience Vaults—Methoxetamine (2011) Suspected overdose, be careful. http://www.erowid.org/experiences/exp. php?ID091291. Accessed 19 July 2011
• Erowid Vaults (2011). Methoxetamine. http://www.erowid.org/ chemicals/ methoxetamine/. Accessed 18 July 2011.
• European Monitoring Centre for Drugs and Addiction-Europol (2011). 2010 Annual Report on the implementation of Council Decision 2005/387/JHA. http://www.emcdda. europa.eu/attachements.cfm/att_132857_ EN_EMCDDA-Europol%20Annual%20 Report% 202010A.pdf Accessed 1 May 2011
• European Monitoring Centre for Drugs and Drug Addiction (2011) Salvia divinorum. http://www.emcdda.europa.eu/publications/drugprofiles/salvia Accessed 20 Aug 2011
• Gertsch, J., Leonti. M., Raduner, S., Racz. I., Chen. J.Z., Xie, X.Q. et al (2008). Betacaryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences USA, 105, (26), 9099–9104.
• Grigoryev, A., Savchuk, S., Melnik, A., Moskaleva, N., Dzhurko, J., Ershov, M. et al (2011). Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879, (15–16), 1126–1136.
• Hanes, K.R. (2001). Antidepressant effects of the herb Salvia divinorum: a case report. Journal of Clinical Psychopharmacology, 21, (6), 634–635.
• Hu, X., Primack. B.A., Barnett, T.E., Cook, R.L. (2011). College students and use of K2: an emerging drug of abuse in young persons. Substance Abuse Treatment, Prevention, and, Policy 6, 16-24.
• Huffman, J.W. (2005). CB2 receptor ligands. Mini Reviews in Medicinal Chemistry 5, (7),641–649.
• Idayu, N.F., Hidayat, M.T., Moklas, M.A., Sharida, F., Raudzah, A.R., Shamima, A.R. et al (2011). Antidepressant-like effect of mitragynine isolated from Mitragyna speciosa Korth in mice model of depression. Phytomedicine, 18,(5), 402–407.
• Johnson, M.W., MacLean, K.A., Reissig, C.J., Prisinzano, T.E., Griffiths, R.R. (2011). Human psychopharmacology and doseeffects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence 115, (1–2), 150–155.
• Kapp, F.G., Maurer, H.H., Auwarter, V., Winkelmann, M., Hermanns-Clausen, M. (2011). Intrahepatic cholestasis following abuse of powdered Kratom (Mitragyna speciosa). Journal of Medical Toxicololgy, 7, (3), 227–231.
• Kaupang, A., Gorbitz, C.H., Hansen, T. (2010). Tert-Butyl 4-(2-diazoacetyl)piperazine-1-carboxyl-ate. Acta Crystallographica Sect E ,66, (Pt 6):o1299.
• Kelly, B.C. (2011). Legally tripping: a qualitative profile of Salvia divinorum use among young adults. Journal of Psychoactive Drugs, 43, (1), 46– 54.
• Kronstrand, R., Roman, M., Thelander, G., Eriksson, A. (2011). Unintentional fatal intoxications with mitragynine and Odesmethyltramadol from the herbal blend Krypton. Journal of Analitycal Toxicology, 35, (4), 242–247.
• Lange, J.E., Daniel, J., Homer, K., Reed, M.B., Clapp, J.D. (2010). Salvia divinorum: effects and use among YouTube users. Drug and Alcohol Dependence 108, (1–2), 138–140.
• Lapoint, J., James, L.P., Moran, C.L., Nelson, L.S., Hoffman, R.S., Moran, J.H. (2011). Severe toxicity following synthetic cannabinoid ingestion. Clinical Toxicology (Phila) 49, (8),760–764.
• Leon, F., Habib, E., Adkins, J.E., Furr, E.B., McCurdy, C.R., Cutler, S.J. (2009). Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Natural Product Communications, 4, (7), 907–910.
• Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L. et al (2009). Spice: a never ending story? Forensic Science International, 191, (1–3), 58–63.
• Marriott, K.S., Huffman, J.W. (2008). Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Current Topics in Medicinal Chemistry, 8, (3), 187–204.
• Maruyama, T., Kawamura, M., KikuraHanajiri, R.,Takayama, H., Goda, Y. (2009) The botanical origin of Kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. Journal of Natural Medicines, 63 (3), 340–344.
• Matsumoto, K., Horie, S., Takayama, H., Ishikawa, H., Aimi, N., Ponglux, D. et al (2005). Antinociception, tolerance and withdrawal symptoms induced by 7 hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sciences, 78 (1), 2–7.
• Matsumoto, K., Mizowaki, M., Suchitra, T., Takayama, H., Sakai, S., Aimi, N. et al (1996). Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Life Sciences, 59, (14), 1149–1155.
• Matsumoto, K., Yamamoto, L.T., Watanabe, K., Yano, S., Shan, J., Pang, P.K. et al (2005) Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sciences, 78, (2), 187–194.
• Mazzoni, O., Diurno, M.V., di Bosco, A.M., Novellino, E., Grieco, P., Esposito, G. et al (2010). Synthesis and pharmacological evaluation of analogs of indole-based cannabimimetic agents. Chemical Biology and Drug Design, 75, (1), 106–114.
• McLachlan, G. (2009). Taking the spice out of legal smoking mixtures. The Lancet 374, (9690):600.
• Moran, C.L., Le, V.H., Chimalakonda, K.C., Smedley, A.L., Lackey, F.D., Owen, S.N. et al (2011). Quantitative measurement of JWH018 and JWH-073 metabolites excreted in human urine. Analitycal Chemistry, 83, (11), 4228–4236.
• Morgan, N.H., Stanford, I.M., Woodhall, G.L. (2009). Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology, 57, (4), 356–368.
• Muller, H., Sperling, W., Kohrmann, M., Huttner, H.B., Kornhuber, J., Maler, J.M. (2010). The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophrenia Research, 118, (1–3), 309–310.
• Mustata, C., Torrens, M., Pardo, R., Perez, C., Farre, M. (2009). Spice drugs: cannabinoids as a new designer drugs. Adicciones, 21, (3), 181–186.
• Nelsen, J.L., Lapoint, J., Hodgman, M.J., Aldous, K.M. (2010). Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. Journal of Medical Toxicology, 6, (4), 424–426.
• NMS labs (2011). NMS Labs Online Test Catalog. http://www.nmslabs.com/servicesforensic-K2-ELISA-FAQ Accessed 30 Oct 2011.
• Pavlopoulos, S., Thakur, G.A., Nikas, S.P., Makriyannis, A. (2006). Cannabinoid receptors as therapeutic targets. Current Pharmaceutical Design, 12, (14), 1751–1769.
• Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P., Di Marzo, V., Elphick, M.R. et al (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacological Reviews 62, (4), 588–631.
• Piggee, C. (2009). Investigating a not-so-natural high. Analytical Chemistry 81, (9), 3205–3207.
• Poso, A., Huffman, J.W. (2008). Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. British Journal of Pharmacology, 153, (2), 335–346
• Przekop, P., Lee, T. (2009). Persistent psychosis associated with Salvia divinorum use. American Journal of Psychiatry, 166, (7), 832-841.
• Roche, K. (2008). Kratom: a case of a legal high. Clinical Toxicology, 46, (7), 598.
• Rosenbaum, C.D., Carreiro, S.P., Babu, K.M. (2012). Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. Journal of Medical Toxicology, 8, 15–32.
• Roth, B.L., Baner, K., Westkaemper, R., Siebert. D., Rice, K.C., Steinberg, S. et al (2002). Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences, USA 99, (18), 11934–11939.
• Scalzo, A. (2010). K2 synthetic marijuana use among teenagersMissouri, 2010. The Epidemic Information Exchange, Missouri.
• Schifano, F., Deluca, P., Baldacchino, A., Peltoniemi, T., Scherbaum, N., Torrens, M. et ál. (2006). Drugs on the web; the psychonaut 2002 0EU project. Progress In Neuropsychopharmacology & Biological Psychiatry, 3, (4), 640–646.
• Schifano, F., Ricciardi, A., Corazza, O., Deluca, P., Davey, Z., Rafanelli, C. (2010). New drugs of abuse on the web: the role of the psychonaut web mapping project. Rivista di Psichiatria 45,(2), 88–93.
• Schmidt, M.M., Sharma, A., Schifano, F., Feinmann, C. (2011). “Legal highs” on the net-evaluation of UK-based websites, products and product information. Forensic Science International, 206, (1–3), 92–97.
• Schmidt, M.S., Prisinzano, T.E., Tidgewell, K., Harding, W., Butelman, E.R., Kreek, M.J. et al (2005). Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 818, (2), 221–225.
• Schwartz, A. (2010). Bong hit gives Miley Cyrus the giggles. http:// www.people. com/people/article/0,,20448642,00.html Accessed 11 Aug 2011
• Sheleg, S.V., Collins, G.B. (2011). A coincidence of addiction to “Kratom” and severe primary hypothyroidism. Journal of Addiction Medicine, 5 (4), 300–301.
• Shellard, E.J. (1974). The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bull Narc, 26, (2), 41–55.
• Siebert, D.J. (1994). Salvia divinorum and salvinorin A: new pharmacologic findings. Journal of Ethnopharmacology, 43, 53–56.
• Simmons, J., Cookman, L., Kang, C., Skinner, C. (2011). Three cases of “spice” exposure. Clinical Toxicology (Phila) 49, (5), 431–433.
• Sobolevsky, T., Prasolov, I., Rodchenkov, G. (2010). Detection of JWH-018 metabolites in smoking mixture post administration urine. Forensic Science International, 200, (1–3), 141–147.
• Staack, R.F. (2007). Piperazine designer drugs of abuse. The Lancet 369, (9571),1411–1413.
• Sulzberger, A., Medina. J. (2011). Shooting suspect had been known to use potent, and legal, hallucinogen. http://www.nytimes.com/2011/01/18/us/18salvia.html Accessed 20 Aug 2011
• Suwanlert, S. (1975). A study of kratom eaters in Thailand. Bull Narc, 27,(3), 21–27.
• Tylden, E., Wild, D. (1967). A case for cannabis? British Medical Journal, 3, (5564): 556.
• Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., Haishima, Y., Goda, Y. (2009). Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chemical and Pharmeutical Bulletin (Tokyo) 57, (4), 439–441.
• US Drug Enforcement Administration (2008). Salvia divinorum and salvorin A. http://www.justice.gov/dea/concern/salvia_divinorum_one_pager.pdf Accessed 20 Aug 2011
• US Drug Enforcement Administration (2011). Salvia divinorum— drug fact sheet. http://www.justice.gov/dea/pubs/abuse/drug_data_sheets/Salvia.pdf Accessed 20 Aug 2011
• Verdurand, M., Dalton, V.S., Zavitsanou, K. (2010). GABA(A) receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain Research, 1351, 238–245.
• Vicknasingam, B., Narayanan, S., Beng, G.T., Mansor, S.M. (2010) The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. International Journal of Drug Policy, 21, (4), 283–288.
• Vohra, R., Seefeld, A., Cantrell, F.L., Clark, R.F. (2011). Salvia divinorum: exposures reported to a statewide poison control system over 10 years. The Journal of Emergency Medicine, 40, (6), 643–650.
• Ward, J., Rhyee, S., Plansky, J. (2011). Methoxetamine: a novel ketamine analog and growing health-care concern. Clinical Toxicology (Phila) 49,(9), 874–875.
• Wood, D.M., Dargan, P.I., Button, J., Holt, D.W., Ovaska, H., Ramsey. J. et ál. (2007). Collapse, reported seizure—and an unexpected pill. The Lancet, 369, (9571): 1490.
• Zawilska, J.B. (2011). “Legal highs”-new players in the old drama. Current Drug Abuse Reviews, 4 ,(2), 122–130.
• Zimmermann, U.S., Winkelmann, P.R., Pilhatsch, M., Nees, J.A., Spanagel, R., Schulz, K. (2009). Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Deutsches Arzteblatt International, 106, (27), 464–467.
• Zuba, D., Byrska, B., Maciow, M. (2011) Comparison of “herbal highs” composition. Analytical and Bioanalytical Chemistry, 400, (1), 119–126.